Second generation

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 

Retrieved on: 
Wednesday, February 28, 2024

SAN CARLOS, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported fourth quarter and full year 2023 financial results and corporate updates.

Key Points: 
  • The Iovance Cell Therapy Center ( iCTC ) began commercial manufacturing for Amtagvi patients within a week of approval.
  • More than 700 patients have been treated with Iovance TIL therapy manufactured using proprietary Iovance processes as of December 31, 2023.
  • Revenue for the fourth quarter and year ended December 31, 2023, was $0.5 million and $1.2 million, respectively, and comprised of product sales following the Proleukin® acquisition in May 2023.
  • Research and development expenses were $87.5 million for the fourth quarter ended December 31, 2023, an increase of $6.9 million compared to $80.6 million for the same period ended December 31, 2022.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • Enrollment of the remainder of this study is ongoing with topline results anticipated in the second half of 2024,” continued Dr. Sommadossi.
  • Final results from the 60 patient lead-in cohort confirmed a 98% SVR4 rate across GT from 58 of 59 patients.
  • Final SVR12 results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $578.1 million at December 31, 2023 compared to $646.7 million at December 31, 2022.

Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days

Retrieved on: 
Monday, March 4, 2024

The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA™ blood Sensor and VORTX™ Orbiting Blood Oxygenation, to delivery oxygen straight into the blood.

Key Points: 
  • The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA™ blood Sensor and VORTX™ Orbiting Blood Oxygenation, to delivery oxygen straight into the blood.
  • The proprietary core technology has undergone a series of testing in a variety of settings, with the results being collected and analyzed.
  • The results refer to the INSPIRA ART (Gen 2), with the new core technology potentially being suitable for replacing current solutions in medical markets dominated by leading medical device companies.
  • The Company plans to announce the primary results around the core blood oxygenation technology of the INSPIRA ART (Gen 2) within days.

AMSOIL INC. Releases New OE 0W-40 100% Synthetic Motor Oil

Retrieved on: 
Friday, March 1, 2024

SUPERIOR, Wis., March 1, 2024 /PRNewswire-PRWeb/ -- AMSOIL has added a new 0W-40 viscosity to its OE 100% Synthetic Motor Oil line to better meet the emerging demands of advanced automotive technology. This new OE 0W-40 is primarily for newer RAM HD trucks equipped with the 6.4L Hemi engine.

Key Points: 
  • AMSOIL OE 100% Synthetic Motor Oil is specifically designed to deliver maximum wear protection, fuel economy and emissions control for the longer drain intervals recommended by original equipment (OE) manufacturers.
  • AMSOIL OE 100% Synthetic Motor Oil is also friendly toward modern emissions-control systems to promote proper operation of catalytic converters for optimum service life and low exhaust emissions.
  • OE 100% Synthetic Motor Oil achieved 100 percent protection against low-speed pre-ignition (LSPI),¹ and it provides 47% more wear protection than required by the GM dexos 1® Gen 2 specification.² AMSOIL OE 100% Synthetic Motor Oil has a 100% synthetic, pure chemical structure engineered to remove harmful contaminants and provide long-lasting engine protection and performance.
  • AMSOIL OE 100% Synthetic Motor Oil is now available in the following viscosities: 0W-16, 0W-20, 5W-20, 5W-30, 10W-30 and 0W-40.

SoCalGas Showcases Zero Emissions Hydrogen Fuel Cell Electric Technologies by Kenworth and Toyota at 2024 World Ag Expo

Retrieved on: 
Monday, February 12, 2024

TULARE, Calif., Feb. 12, 2024 /PRNewswire/ -- Southern California Gas Company (SoCalGas) alongside Kenworth Truck Company (Kenworth) and Toyota Motor North America Inc. (Toyota) are displaying two zero emissions hydrogen fuel cell electric vehicles (FCEV) at the annual World Ag Expo this week. SoCalGas' booth will showcase Kenworth's Class 8 T680 hydrogen FCEV truck powered by Toyota, as well as one of SoCalGas's zero emissions fleet vehicles, a hydrogen fuel cell electric Toyota Mirai. As part of SoCalGas' ASPIRE 2045 sustainability strategy, SoCalGas has converted 38% of its over-the-road fleet to run on alternative fuels like hydrogen, renewable natural gas, and battery electric. The company aims to continue growing its alternative fuel vehicle (AFV) fleet, with an interim goal of reaching a 50% AFV powered fleet by 2025 and a 100% zero emissions fleet by 2035.   

Key Points: 
  • TULARE, Calif., Feb. 12, 2024 /PRNewswire/ -- Southern California Gas Company (SoCalGas) alongside Kenworth Truck Company (Kenworth) and Toyota Motor North America Inc. (Toyota) are displaying two zero emissions hydrogen fuel cell electric vehicles (FCEV) at the annual World Ag Expo this week.
  • SoCalGas' booth will showcase Kenworth's Class 8 T680 hydrogen FCEV truck powered by Toyota, as well as one of SoCalGas's zero emissions fleet vehicles, a hydrogen fuel cell electric Toyota Mirai.
  • As part of SoCalGas' ASPIRE 2045 sustainability strategy , SoCalGas has converted 38% of its over-the-road fleet to run on alternative fuels like hydrogen, renewable natural gas, and battery electric.
  • Also on display at the booth is one of SoCalGas' zero emissions hydrogen fleet vehicles, the Toyota Mirai, which uses a hydrogen fuel cell to generate the electricity that powers the vehicle.

Integer to Showcase Recently Acquired Capabilities and New Technologies at MD&M West 2024

Retrieved on: 
Thursday, February 1, 2024

PLANO, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leader in medical device outsource manufacturing, will join innovators and industry leaders around the world in exhibiting at MD&M West, Feb. 6-8, 2024, at the Anaheim Convention Center in Anaheim, California.

Key Points: 
  • Integer’s exhibit will spotlight the recent strategic acquisitions of InNeuroCo and Pulse Technologies, each of which have further enhanced Integer’s capability spectrum in the medical device sector.
  • The acquisition of InNeuroCo brings specific expertise in neurovascular solutions and advanced catheter technologies, while the combination with Pulse Technologies enhances capabilities in precision micro machining, backed by proprietary technologies and a focus on high-growth medical markets.
  • Cardio and Vascular Solutions: A full range of electrophysiology, structural heart, and neurovascular product solutions including high-performing guidewires, steerable introducers and sheaths, therapy delivery systems, and implant technologies.
  • In addition to Integer’s exhibit at booth #1439, MD&M West 2024 attendees can also visit Pulse Technologies at booth #2844 to learn more about complex micro machining for critical medical device components.

Cynerio Strengthens Its Partner Ecosystem in North America to Combat Rising Healthcare Cyber Threats

Retrieved on: 
Tuesday, December 5, 2023

NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Cynerio, a leading provider of 2nd Generation cybersecurity solutions for healthcare IoT, proudly announces the significant expansion of its partner ecosystem throughout North America.

Key Points: 
  • NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Cynerio, a leading provider of 2nd Generation cybersecurity solutions for healthcare IoT, proudly announces the significant expansion of its partner ecosystem throughout North America.
  • With the addition of multiple strategic partners, Cynerio is reinforcing its commitment to fortifying the healthcare industry against the escalating wave of cyberattacks and ransomware incidents that threaten hospitals and patient care globally.
  • As healthcare organizations strive to transition from device visibility to actionable protections, they encounter challenges ranging from inaccurate device details to ineffective creation of untested network policy rules.
  • Reseller Program Benefits: Partners in this category gain exclusive access to state-of-the-art cybersecurity solutions tailored to address the intricate challenges of healthcare IoT environments.

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • We’ve quickly completed enrollment of the   60-patient lead-in cohort and initial results are expected in early 2024," continued Dr. Sommadossi.
  • Currently, Atea anticipates providing an update after each of these interim analyses are completed with the first update expected to occur in the first quarter of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $595.1 million at September 30, 2023 compared to $608.1 million at June 30, 2023.
  • Income Tax Expense: Income tax expense was $0.2 million for the quarter ended September 30, 2023 compared to a benefit of $3.8 million for the quarter ended September 30, 2022.

Global Anti-Epileptic Drugs (AEDs) Market Set to Reach $11.47 Billion by 2028 with a Steady 3.39% CAGR, Fueled by Improved Effectiveness and Patient Compliance - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023

This growth is attributed to the increasing effectiveness of AEDs in controlling seizures, accompanied by fewer side effects, resulting in improved patient compliance.

Key Points: 
  • This growth is attributed to the increasing effectiveness of AEDs in controlling seizures, accompanied by fewer side effects, resulting in improved patient compliance.
  • Anti-Epileptic Drugs (AEDs) have evolved significantly in recent years, becoming central in addressing various epilepsy-related syndromes and offering tailored care for patients.
  • By Drug Generation: The global AEDs market is segmented into First Generation, Second Generation, and Third Generation.
  • Post-pandemic, the anti-epileptic drugs market landscape underscores the need for enhanced supply chain resilience and integrated digital healthcare.

Scent-flavored hydration leader air up® launches new Generation 2 bottle made with Tritan™ Renew

Retrieved on: 
Tuesday, October 31, 2023

The new air up® Generation 2 bottles made with Tritan Renew are manufactured in the European Union at production facilities that use 100% renewable energy and use up to 88% less plastic than single-use plastic bottles.

Key Points: 
  • The new air up® Generation 2 bottles made with Tritan Renew are manufactured in the European Union at production facilities that use 100% renewable energy and use up to 88% less plastic than single-use plastic bottles.
  • The collection is lightweight, shatter-resistant and available in two sizes — 600 milliliter and 1 liter — from air up ® .
  • air up® is the world's first refillable drinking system with retronasal smell, where plain water is flavored through scent alone.
  • "This partnership reflects our shared strong commitment to combating the global plastic waste crisis, while providing innovation to the hydration market."